Clinical Decision Support Tool in PARDS Pilot Study
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- Children's Hospital Los Angeles
- Study ID
- NCT04068012
- Status
- Recruiting
Conditions
- Ards
- Ventilation Therapy; Complications
- Ventilator-Induced Lung Injury
Eligibility Criteria
- Sex
- ALL
- Age
- 1 Month - 18 Years
- Healthy Volunteers
- Not accepted
Interventions
- Ventilator protocol — OTHERopen loop ventilator management by a computer based protocol
Study Details
Previous clinical trials in adults with acute respiratory distress syndrome (ARDS) have demonstrated that ventilator management choices can improve Intensive Care Unit (ICU) mortality and shorten time on mechanical ventilation. This study seeks to scale an established Clinical Decision Support (CDS) tool to facilitate dissemination and implementation of evidence-based research in mechanical ventilation of infants and children with pediatric ARDS (PARDS). This will be accomplished by using CDS tools developed and deployed in Children's Hospital Los Angeles (CHLA) which are based on the best available pediatric evidence, and are currently being used in an NHLBI funded single center randomized controlled trial (NCT03266016, PI: Khemani). Without CDS, there is significant variability in ventilator management of PARDS patients both between and within Pediatric ICUs (PICUs), but clinicians are willing to accept CDS recommendations. The CDS tool will be deployed in multiple PICUs, targeting enrollment of up to 180 children with PARDS. Study hypotheses: 1. The CDS tool in will be implementable in nearly all participating sites 2. There will be \> 80% compliance with CDS recommendations and 3. The investigators can implement automatic data capture and entry in many of the ICUs Once feasibility of this CDS tool is demonstrated, a multi-center validation study will be designed, which seeks to determine whether the CDS can result in a significant reduction in length of mechanical ventilation (LMV).
Key Dates
- Start date
- Dec 1, 2020
- Status verified
- Apr 2026
- Primary completion
- Jul 31, 2027
- Completion
- Jul 1, 2027
Study Design
- Enrollment
- 180 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- PREVENTION
Arms
- Experimental: InterventionVentilator management using the proposed protocol in both acute and weaning phases
Primary Outcome Measure
Aim 1: Implementation Feasibility [ Time Frame: through study completion - each patient will be capped at 28 days, limitation of care, or death, whichever comes first. ]
Central Contacts
- Christopher J Newth, MD3233612557
- Robinder G Khemani, MD3233612376
Locations (6)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois | 60611 | Lazaro Sanchez-Pinto |
| Riley Hospital for Children | Indianapolis | Indiana | 46202 | Samer Abu-Sultaneh |
| Penn State University | Hershey | Pennsylvania | 17033 | Neal Thomas |
| University of Utah | Salt Lake City | Utah | 84112 | Anna Hubbard |
| University of Wisconsin-Madison | Madison | Wisconsin | 53715 | Awni Al-Subu |
| Children's Hospital of Wisconsin | Milwaukee | Wisconsin | 53226 | Prakadeshwari Rajapreyar |
Find similar trials in Chicago, IL
Related Studies
- Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)PHASE3 · Recruiting · Direct Biologics, LLC · Phoenix, Arizona
- The APS Phenotyping StudyRecruiting · Vanderbilt University Medical Center · Fresno, California
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: BevacizumabPHASE2 · Recruiting · PPD Development, LP · Birmingham, Alabama
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: ParidiprubartPHASE2 · Recruiting · PPD Development, LP · Birmingham, Alabama